Brief: Adaptive Biotechnologies Announces New Data Demonstrating The Benefit Of Serial Mrd Testing With The Clonoseq® Assay In Patients With Blood Cancers At The 63Rd Ash Annual Meeting
13/12/2021 22:38
Dec 13 (Reuters) - Adaptive Biotechnologies Corp ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING
THE
BENEFIT OF SERIAL MRD TESTING WITH THE CLONOSEQ® ASSAY IN
PATIENTS WITH BLOOD CANCERS AT THE 63RD ASH ANNUAL MEETING
Source text for Eikon: ID:nGNX8thkYh
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsAdvisory: Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary
Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates